Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial

Authors:

Abstract
No abstract available
Funding Information
  • Altimmune Inc

This publication has 33 references indexed in Scilit: